MAPT and mild neurocognitive disorder: Clinical subgroup analysis, to determine whether there were disease-specific effects, showed that PROG low-expressors were significantly associated with FTD-MND [Exp(B)=5.0, adjusted P=0.037] and CBS status [Exp(B)=5.9, adjusted P=0.037], but not with the other Tau-based subgroups, PSPS and PNFA (Table 1).